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Activity-based probeThe largest mammalian enzyme family is the kinases. Kinases and other nucleotide-binding pro-
teins are key regulators of signal transduction pathways and the mutation or overexpression of
these proteins is often the difference between health and disease. As a result, a massive research
effort has focused on understanding how these proteins function and how to inhibit them for ther-
apeutic beneﬁt. Recent advances in chemical biological tools have enabled functional interrogation
of these enzymes to provide a deeper understanding of their physiological roles. In addition, these
innovative platforms have paved the way for a new generation of drugs whose properties have been
guided by functional proﬁling.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. The beginnings of activity-based proteomics
The origins of activity-based proteomic proﬁling (ABPP) can be
found in the growth of bio-organic chemistry and mechanistic
enzymology that emerged post-World War II [1–3]. Intense inter-
est blossomed in understanding the nature of enzymatic catalysis
in the context of the physical organic principles that govern the
conversion of substrate to product and the structural elements of
the enzyme/substrate interactions that lead to the remarkable rate
accelerations that enzymes can achieve. Major advances in this
understanding of enzyme action came from the design and analysis
of small molecules, such as afﬁnity labels and mechanism-based
inhibitors, which could modify the enzyme in speciﬁc ways to re-
veal the mechanistic and structural aspects of catalysis in an era
that largely pre-dated the stunning advances in and accessibility
to structural biology instrumentation (for early successes, see
[4,5]).
This early work was critical to the understanding of catalysis
and also the appreciation that common mechanistic motifs and
structural elements united enzymes into families that could poten-
tially be interrogated with common chemical probes. The work
over 60 years ago on the stoichiometric inhibition of serine
hydrolases, such as chymotrypsin, trypsin, and cholinesterase, by
diisopropyl ﬂuorophosphate [6–8] is the lineal ancestor of serinehydrolase ABPP that has become the signature work of the ﬁeld
[9,10,2].
The advances in genomics, separations technologies and mass
spectrometry were instrumental in the transition from enzyme
chemistry to proteomic chemistry that ABPP represents. The ability
to move protein puriﬁcation from an upfront, often long and
tedious, procedure to a back-end deconvolution of native proteo-
mic mixtures has greatly expanded and accelerated the data anal-
ysis as will be discussed. In addition, the proteomic mixture
provides a richer substrate to explore the effect of protein–protein
and other cellular interactions that can affect ABPP and gives clues
to the cellular behavior of enzymes, their substrates and inhibitors.
In this review, we will focus on the development of ABPP for the
protein kinases (PKs) that comprise the kinome. The challenge that
interrogation of the kinome by ABPP presents is daunting and
multifaceted. Several approaches have been explored with varying
degrees of success and will be discussed.
2. The kinome challenge
The human kinome consists of a nonredundant set of 518 PK
genes, divided into 9 groups, 134 families and 201 subfamilies
[11]. It is the largest enzyme complement in mammals constituting
1.7% of the human genome. Despite the broad range of percent
protein sequence identities among kinome members, sequence
comparisons have shown that virtually all PKs have at least one
conserved lysine residue within their active sites. The ATP binding
loop region contains one lysine residue in all ‘‘typical’’ PKs with
Fig. 1. Components involved in functional interrogation of kinases and other
nucleotide-binding proteins. These systems determine binding of a probe (upper
box), which includes isolation and recognition elements, to target proteins (lower
box), which are either endogenous proteins identiﬁed after isolation by mass
spectrometry, or fusion proteins wherein the protein is identiﬁed by analysis of
fused nucleotides. Optionally, binding between probe and targets can be competed
by soluble test inhibitors to quantitatively characterize inhibitor/target binding
properties.
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the C-terminus of the catalytic aspartic acid of the HRDLK motif
in the majority of serine/threonine kinases. These two motifs,
along with other areas of the protein, play a major role in the bind-
ing of ATP, the common substrate for all PKs, and the catalysis of
the phosphoryl group transfer of the c-phosphate of the ATP to
the protein substrate.
The key role of the PKs in a wide range of complex cellular sig-
naling functions and pathway cascades makes them prime candi-
dates as targets for drug design [14–17]. This is reinforced by the
fact that nearly half of the 518 human PKs have been mapped to
disease loci or cancer amplicons. In addition, the design of inhibi-
tors of the common ATP binding site has been most tractable for
the medicinal chemists. Thus, a major challenge has been design-
ing potent competitive inhibitors of ATP for the target kinase that
also demonstrates acceptable selectively against the rest of the ki-
nome – a considerable challenge (for notable recent successes, see
[18–20]).
A potentially greater challenge of kinome drug discovery is the
issue of species differences. Not surprisingly, speciﬁc kinases show
species variability in their primary protein sequences that can lead
to differences in potency that must be considered in preclinical
animal and toxicology models. This is a common problem in most
discovery projects regardless of the target under investigation.
However, other kinomes of other species suggests that this prob-
lem goes deeper.
Consider the mouse kinome [21]. The mouse is arguably the
preeminent species for early efﬁcacy and toxicity analysis of
preclinical drugs. The mouse kinome is the probably the best
understood behind the human. There are 540 predicted PKs in
the mouse kinome with orthologues for 510 of the 518 human
PKs. Eight human PKs have no mouse orthologues; the mouse
has 40 unique orthologues. Some of these unique orthologues
can be traced to gene loss, retrotransposition, and incomplete
genome sequence. Orthologous kinase pairs vary in sequence con-
servation along their length, with many species-speciﬁc sequence
inserts exist and alternative splicing. There are 97 mouse PK pseu-
dogenes that are all distinct from the 107 human PK pseudogenes.
In other kinomes, greater differences appear. Remarkably, the
chimpanzee kinome has 587 predicted PKs. No human orthologue
with greater than 95% sequence identity could be identiﬁed for
160 PKs. Variations in chimpanzee kinases compared to human ki-
nases are brought about also by differences in functions of do-
mains tethered to the catalytic kinase domain [22]. Little
published work on other kinomes is available so they must be con-
sidered works-in-progress. Based on a library of hidden Markov
models (see http://www.compbio.dundee.ac.uk/kinomer [23]),
the rat kinome has 521 predicted PKs and the dog kinome, 656
PKs. Even allowing for revisions and modiﬁcations of these data,
it is clear that signiﬁcant interspecies differences will exist among
higher mammalian kinomes. From a drug development perspec-
tive, these differences can be highly problematic. Since drug candi-
dates are evaluated in a number of accepted preclinical species
(such as mouse, rat, dog and non-human primate) for toxicity
and, in some cases, efﬁcacy, the potential for a kinase inhibitor
to have different selectivity and off-target proﬁles in the kinomes
of different species is potentially signiﬁcant. Thus, if a toxicity sig-
nal is observed in the dog for example, the development team is
faced with the problem of determining if the signal suggests tox-
icity relevant to the human use of the drug or if it is idiosyncratic
to the dog kinome.
Substrate-based, recombinant kinase proﬁling platforms are
largely focused on a large library recombinant human PKs; the ki-
nomes of other species have not been as extensively cloned to pro-
vide broad proﬁling capabilities. Developing a general kinase assay
that could function across the kinomes of virtually all specieswould be a breakthrough in the ﬁeld and greatly beneﬁcial in
understanding comparative cross-species responses.
3. Non-activity based kinome proﬁling platforms
As interest in PKs as mediators of key biological processes has
grown, numerous elegant solutions have been proposed for the
study of these proteins en masse (see Fig. 1). Kinases as a class have
several features in common, perhaps most signiﬁcant is the
common use of ATP as a co-substrate. While having a class of over
500 proteins with common active site features has made drug
discovery difﬁcult, it has in many ways simpliﬁed the task of estab-
lishing class-wide analysis platforms. All of the proﬁling platforms
have in common the ability to determine competition between a
test compound and a known probe compound, which is typically
either ATP itself or a broadly non-selective inhibitor. Differences,
described below, among the platforms include: whether the probe
is bound to a resin or free in solution; whether the probe binds
covalently to target proteins or not; for covalent probes, whether
they bind via mechanism-based interaction or via photoactivated
labeling; and ﬁnally the kinases are identiﬁed either by mass spec-
trometry of naturally occurring protein or by genetic methods by
making use of kinase/nucleic acid fusions. The availability of these
very broad kinase proﬁling methods combined with the demon-
stration that limited subsets of kinases are unable to accurately
indicate compound selectivity have thrust these methods into
the mainstream of drug discovery. Additionally, the ability to iden-
tify kinases based on an intact active site from natural extracts has
provided a very useful addition to broad shotgun-style proteomic
and genomic analyses.
One of the original large-scale kinase proﬁling platforms made
use of a library of recombinant kinases expressed on the surface
of T7 bacteriophage [24]. By determining number of phage parti-
cles bound to immobilized kinase inhibitors in the presence of a
titration of free test compound, the assay could determine potency
of test compound for the displayed kinase. From 113 kinases in
2005, this platform has expanded to cover at least 440 assays,
including protein and lipid kinases, oncogenic or drug resistant
mutants, and several kinases from pathogens [25]. Originally
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through DiscoveRx Corporation. In the current version of this as-
say, kinases are fused to either T7 bacteriophage or NF-jB. In the
case of kinases bound to NF-jB, DNA is subsequently tagged to
the fusion protein, which permits quantitation by PCR. One of
the key contributions to the ﬁeld provided by this assay was the
observation that selectivity screening within single small panels
can be highly misleading [26]. Thorough analysis of Kamaran,
et al.’s data showed that it is impossible to identify a representative
group of kinases for selectivity screening, and that inhibitors can
target isolated clusters of targets widely distributed throughout
the kinome dendrigram.
An alternative method essentially derived from classical afﬁnity
chromatography has been recently described [27,28]. Like the pre-
vious method, an essential component of the afﬁnity chromatogra-
phy method is beads containing immobilized, non-selective kinase
inhibitors. Kinase-containing cell or tissue extracts are bound to
beads in the presence of deﬁned concentrations of test inhibitors.
Careful biochemical treatment and mass spectrometry, have been
shown through extensive validation, to result in quantitative
assessments of compound/kinase interactions [29]. A key advance
over previous afﬁnity chromatography approaches is the ability to
avoid bespoke synthesis of immobilized versions of every novel
compound. In contrast to the phage-based screening methods, ki-
nases proﬁled by mass spectrometry are analyzed in their native
post-translational forms, with their natural binding partners. This
method was developed by Cellzome (now a part of GlaxoSmithK-
line plc.) and Kinaxo Biotechnologies GmbH (now Evotec Munich).
Another approach (sometimes called compound capture mass
spectrometry) uses trifunctional probes that contain selectivity,
reactivity and sorting domains. Reported selectivity domains in-
clude kinase inhibitors [30], and nucleotides [31], while reactivity
and sorting domains are typically photoreactive functionalities and
biotin (or click-able motifs), respectively. In the case of stauro-
sporine, a large scale mass spectrometry experiment identiﬁedFig. 2. (Left) Chemical structure of the ATP or ADP acyl phosphate probe, showing the
(Right) Model of the ATP acyl phosphate probe bound to the active site of CDK2, showing
found in the ATP binding loop of all protein kinases except for the WNK sub-family. Ly
kinases.100 kinases using a staurosporine/biotin-containing capture com-
pound in extracts of a human cell line, whereas 223 non-kinase
proteins were also enriched with the staurosporine capture com-
pound [32]. Such trifunctional probes are commercially available
from Caprotec Bioanalytics GmbH. A complementary approach
using a cell permeable staurosporine/alkyne probe that was clicked
after photoactivation was used to identify 43 kinases from a hu-
man cell line [33]. A recent example described comparable probes
that contained recognition elements from type II kinase inhibitors,
which could prove complementary to type I or ATP-derived recog-
nition element-containing probes [34].
4. The development of a nearly ideal ATP probe
The search for an ATP probe capable of broadly interrogating
ATP binding space in complex proteomic samples has become
something of a Holy Grail for well over 40 years [35]. Probably
the most extensively studied has been the afﬁnity reagent 50-ﬂuor-
osulfonylbenzoyl-50-adenosine (FSBA). FSBA has been used to iden-
tify ATP-binding sites in kinases because it reacts with nucleophilic
amino acids residues and covalently modiﬁes conserved lysines
present in the nucleotide-binding site of kinases. FSBA has been
incorporated into a proteomics platform with modest results [36].
FSBA has a number of shortcomings as an ATP probe. Most
apparent, aside from the adenosine moiety, it is a poor ATP analog.
Uncharged, hydrophobic and with marginal solubility, FSBA has
relatively weak binding afﬁnity for ATP sites in general. The elec-
trophilic ﬂuorosulfonyl group will react with lysines in some ATP
binding sites but can also react with other nucleophilic amino acid
residues, which can complicate analysis (see for example [37]).
Clearly, better ATP probes are needed.
At ActivX Biosciences, we were struck by the chemistry of acyl-
phosphates as potentially offering a suitable platform for ATP probe
design (Fig. 2). The simplest member of this family is acetyl phos-
phate, a naturally-occurring, high-energy phosphate intermediatereaction mechanism of the acyl phosphate with a lysine residue in the active site.
the proximity of the acyl phosphate group to conserved lysine residues. Lysine 1 is
sine 2 is found at the C-terminus of the catalytic Aspartate in all serine/threonine
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mann [38,39] and studied mechanistically by Jencks [40,41], acetyl
phosphate is a compact juxtaposition of an electrophilic acetyl
group and a reactive phosphate. Pertinent to our discussion, the
acetyl group is highly susceptible to nucleophilic attack on the car-
bonyl moiety by primary amines resulting in the formation of the
corresponding acetamide and phosphate via C–O bond cleavage.
The proximity of conserved lysine residues to the phosphate back-
bone of ATP in the ATP binding site (vide supra) suggested that an
acylphosphate, appropriately designed with recognition elements
could result in an effective ATP probe. Clearly, adenosine recogni-
tion would be a requirement.
Acylphosphates of 50-AMP are known biological intermediates
in a large variety of acyl transferase reactions, such as aminoacyl
tRNA synthetases and other ATP-dependent acyltransferases. The
literature on these intermediates is extensive (for examples, see
[42,43]). The positioning of the acylphosphate and adenosine
moiety suggested the possibility that an acylAMP-based probe
could be useful. Our early work with this probe was mildly encour-
aging but suffered from weak signals in proteomic samples and
comparatively high backgrounds due to non-speciﬁc labeling of
surface lysines (unpublished results).
We concluded that an acyl phosphate of ATP and/or ADP would
provide the best binding and placement of the acyl group. The
literature on these nucleotide analogs is sparse, focused on the
synthesis of lipophilic acylphosphates of ATP for membrane trans-
port of the nucleotide [44,45]. Using the general chemical proce-
dures described in those studies, the ActivX ATP and ADP probes
have been designed with the acyl moiety bearing a biotin or desthi-
obiotin group for peptide capture (vide infra). The ATP/ADP probes
are synthetically simple, stable in amine-free solution for days
under neutral conditions and are patented. The probes also show
broad PK labeling as will be discussed.
5. The ActivX KiNativ platform
When the ATP or ADP acyl phosphate probes are added to a
complex proteome, they efﬁciently label not only lysine residues
in the active sites of protein and lipid kinases, they also label the
active sites of non-kinase ATPases, as well as other nucleotide
binding proteins (see Fig. 2 and [12]). Inevitably, non-speciﬁc
surface lysine residues are also modiﬁed by the probes. Therefore,
the technical challenge in utilizing the probe to efﬁciently proﬁleFig. 3. Workﬂow of a KiNativ experiment. Lysates (typically prepared in 20 mM HEPES
inhibitor, followed by labeling with 5 lM probe. Samples are then denatured with urea, r
with streptavidin, eluted, and analyzed by mass spectrometry.protein and lipid kinases is the development of methods that allow
for the speciﬁc quantitation of the relevant peptides of kinases, in
spite of the abundance of non-kinase probe labeled peptides that
potentially interfere with the proﬁling of the relevant targets
(Fig. 3).
During the development of protocols for characterizing probe-
labeled peptides in complex proteomes, we quickly realized that
for best reproducibility, and potential automation, solution tryp-
sinization of samples followed by the enrichment of probe-labeled
peptides by streptavidin, were superior to the more traditional
methods of whole protein capture followed by resolution by 1D
or 2D SDS–PAGE. In the protocol eventually established, lysates
are typically labeled with 5 lM probe for 10 min in the presence
of 20 mM MnCl2. Under these conditions, the majority of kinases
are not yet labeled to completion. As a result, IC50 values measured
for the competition between inhibitors and the probe are usually a
good estimation of the Kd values. Samples are then denatured with
urea, reduced, alkylated and desalted by gel-ﬁltration, trypsinized,
and the probe-labeled peptides captured by streptavidin. Probe-la-
beled peptides are then eluted, and analyzed by mass spectrometry
(Fig. 3). As the probe–peptide adduct is chemically stable, the sam-
ples can be rigorously washed, thereby ensuring the highest possi-
ble quality of samples for mass spectrometry analysis. The entire
process has been automated, and is currently executed in a 96-well
format.
Initially, the analysis was done on LC–MS/MS ion trap instru-
ments in data dependent mode. In this acquisition mode, the mass
spectrometer requires the signal strength in the parent ion (MS)
spectrum to be in the top 10–20 ions before a fragment spectrum
is collected. During the course of this analysis, we veriﬁed that for
most part, the surface lysine probe-labeled peptides do not signif-
icantly interfere with our ability to proﬁle active site probe-labeled
peptides. The overall labeling rate of surface lysine residues is sig-
niﬁcantly slower than the labeling rate of active site residues (1st
order versus 2nd order reactions). Although in total, there are a
very large number of surface lysine probe-labeled peptides, these
peptides are very diverse, and during the course of the liquid chro-
matography that precedes MS, these peptides are ‘‘diluted’’
throughout the LC gradient, and the individual signals of these
peptides are lost in the noise of the MS signal.
However, in a proteome labeled with the acyl phosphate probe,
there could still be as many as 1000 different probe-labeled pep-
tides derived from active site lysine probe labeled peptides ThepH 7.5, 150 mM NaCl, 0.1% Triton-X-100, 20 mM MnCl2) are treated with/without
educed, alkylated, gel-ﬁltered and trypsinized. Probe-labeled peptides are captured
1874 J.S. Rosenblum et al. / FEBS Letters 587 (2013) 1870–1877fraction and relative signals of active site kinase peptides are rela-
tively low compared to the probe-labeled peptides of other ATPas-
es and nucleotide binding proteins. As a result, our ability to
accurately and reproducibly quantitate kinase probe-labeled pep-
tides, particularly from low abundance kinases was generally poor.
In order to overcome these technical challenges, we devised a
mass spectrometry approach termed ‘‘targeted analysis’’. In this
approach, the instrument is pre-programmed to collect MS/MS
data on known kinase peptide ions at speciﬁed times. The
approach does require a priori knowledge of the expression of spe-
ciﬁc kinases in a particular proteome. In a typical workﬂow for set-
ting up a target list for a new proteome, the probe-labeled peptides
in the proteome are thoroughly analyzed in data dependent mode
to identify all the kinase active site probe-labeled peptides present
using the Sequest algorithm. Based on this information, the mass to
charge ratios of the kinase peptides are assembled into a time-seg-
mented target list. Scan rate limitations may restrict the number of
individual peptides targeted during a mass spec run. However, it is
worth noting that technical improvements to ion trap instruments
resulting in faster scan rates currently allow for 350 unique
peptides to be targeted during a single mass spec run.Fig. 4. KiNativ kinome coverage. Kinases that have been labeled in cell and/or tissueThe principal advantage of the targeted method over the data
dependent method is that quantitation of probe labeled peptides
can now be done in MS/MS mode rather than directly quantitating
the parent ion peak. In MS/MS quantitation, the mass to charge
value of the parent ion of interest is ﬁrst used to ﬁlter the signal.
Quantitation is then carried out using the MS/MS fragment ions
of the probe-labeled peptide. Using this approach, the signal to
noise ratios of probe-labeled peptides are boosted >50-fold com-
pared to quantitating the parent ion peak.
In order to comprehensively proﬁle kinases in a proteome, best
results are obtained using both the ATP and ADP acyl phosphate
probes. Although the overall kinase proﬁles are very similar be-
tween both probes, differences in the positioning of the acyl phos-
phate groups between the ATP and ADP probes relative to the
active site lysine residues may inﬂuence the labeling rate of the
probe with the lysine residues. In particular, the Lysine 1 sites tend
to label with the ADP probe, while activation loop peptides (DGF
motif) tend to label better with the ATP probe. More importantly,
when proﬁling non type I kinase inhibitors, the choice of probe
may dramatically affect whether or not competition is observed
between the inhibitor and the probe. We recently observed thatextracts with the ATP- (or ADP-) acylphosphate probes are highlighted in red.
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the ADP probe. Possibly, the relative positioning of the acyl phos-
phate sterically clashes with the inhibitor only in the case of the
ATP probe, but not the ADP probe.
The accumulation of numerous mass spectrometry runs in
either data dependent or targeted mode has allowed us to generate
a comprehensive database of curated probe-labeled peptides. To
date, we have validated active site probe-labeled peptides corre-
sponding to almost 400 human protein and lipid kinases (Fig. 4).
Using this information, we have been able to establish a ‘‘master’’
target list covering almost 400 unique protein and lipid kinases.
This master target list has been an invaluable tool towards interro-
gating the kinase proﬁles of new proteomes. Additionally, we have
also validated about 1000 kinase active site peptides from mouse,
rat, monkey and dog.6. Applications of kinome proﬁling
At a fundamental level, the KiNativ platform is a tool to proﬁle
native kinases in complex proteomes. This unique aspect of the
platform sets it apart from most other kinase proﬁling platforms,
and truly allows it to bridge the different facets of the drug discov-
ery process.
One of the principal applications of the KiNativ platform is the
selectivity proﬁling of kinase inhibitors. On the surface, this appli-
cation may appear conceptually similar to proﬁling inhibitors
against panels of recombinant kinases. However, in many cases,
recombinant kinase assays are established using only the minimal
kinase domain, rather than the full-length protein. Should the
additional domains of the full-length kinase modulate the interac-
tion between an inhibitor and kinase domain, the results of the
recombinant enzyme assay may have no relevance to the perfor-
mance of the inhibitor against the native kinase. In contrast, on
the KiNativ platform, the proﬁling is done against full-length
native kinases in the context of post-translational modiﬁcations
and binding partners. It is also worth noting that at some point
during the drug discovery process, compounds will have to be
tested in various animal models to verify both safety and efﬁcacy.
The KiNativ method allows for the determination of the binding
afﬁnity of a compound for its kinase target in any species by pro-
ﬁling the compound in the appropriate lysate. This approach is sig-
niﬁcantly more straightforward than having to clone, express and
potentially optimize assays for recombinant kinases form different
species.
One of the challenges during the drug discovery process is cor-
relating inhibition of the target (target engagement) with efﬁcacy
in either a cell based assay (e.g., inhibition of cytokine release, cell
death), or an animal study (e.g., shrinkage of a tumor). The KiNativ
platform allows for the direct determination of target engagement
in a relevant cell line or animal tissue in parallel to the cellular or
animal studies, thereby allowing for correlation between target
engagement and efﬁcacy. For example, a compound showing
potent inhibition against its target in vitro may show no efﬁcacy
in an in vivo animal study. The KiNativ platform allows for direct
interrogation of the inhibition of the target in a relevant tissue
form this animal study. If the target was not inhibited, then the
compound may have pharmacokinetic liabilities, and medicinal
chemistry efforts should be directed towards addressing these is-
sues. On the other hand, if the target was potently inhibited, but
no efﬁcacy observed, there is a possibility that the target may
not be relevant for the indication being explored.
As a kinase inhibitor advances through the drug discovery
process, understanding the impact of the inhibitor on other kinase
transduction pathways may be critical towards uncovering
potential liabilities of the inhibitor. For example, selective B-RAFinhibitors have been shown to activate C-RAF and/or A-RAF, result-
ing in hyper-phosphorylation of ERK1 and ERK2 [46,47]. In fact,
through proﬁling cells treated with various B-RAF inhibitors,
including vemurafenib, on the KiNativ platform, we were able to
detect signiﬁcant increases in the probe labeling of both A-RAF
and C-RAF [48]. These increases in probe labeling could be due to
the activation of these kinases resulting from the inhibition of B-
RAF. More recently, we have also demonstrated that the treatment
of cells with the EGFR inhibitor erlotinib results in an increase in
the probe labeling of ErbB2. We believe that in applying the KiNa-
tiv platform to proﬁling cells or tissues undergoing longer-term
treatment with an inhibitor (hours to days) will not only conﬁrm
the direct targets of the inhibitor but also identify other pathways
perturbed by the kinase inhibitor.
The applications described so far demonstrate the value of the
KiNativ platform towards the progression of drug discovery efforts.
We believe that for the potential of the KiNativ platform to be fully
realized, the platform should be used to evaluate material obtained
from patients in clinical trials. We have recently optimized a pro-
tocol in which a compound is directly added to whole blood, the
white blood cells isolated, lysed, probe-labeled and inhibition of
the target determined by mass spectrometry. In principle, this ap-
proach should be directly applicable to measuring target engage-
ment from blood drawn from patients undergoing drug treatment.7. Expanding the technology (non-kinase targets)
A recent report detailed the use of a photoactive nucleotide
derivative that also contained an alkyne (GTP-BP-yne) to identify
components of the GTP-ome [49]. Importantly, like other methods
using random covalent labeling, and unlike the nucleotide acyl-
phosphate approach, this approach does not require an appropri-
ately positioned active site lysine for modiﬁcation and
subsequent MS identiﬁcation of the bound protein. Once the rela-
tively small GTP-BP-yne probe binds target proteins in a lysate, the
probe is photoactivated to react with bound proteins, followed by
click chemistry to isolate the probe–protein complex. In a broad
proteomic survey of GTP-BP-yne targets in a human cell line, 33
proteins were identiﬁed in each of 3 duplicate experiments, includ-
ing many known GTP-binding proteins and several identiﬁed as
GTP binders for the ﬁrst time.
Several applications of acylphosphate-containing probes have
recently been described. In one application, an ATP acylphosphate
probe was used to identify differentially expressed proteins upon
diet-induced obesity in mice [50]. In this experiment, almost 300
ATP-binding proteins were identiﬁed from skeletal muscle mito-
chondria, more than 50 of which were differentially abundant be-
tween mice on standard diet and high-fat diet. Proteins were
identiﬁed from a number of vital mitochondrial pathways, includ-
ing oxidative phosphorylation and lipid metabolism. As numerous
reports of overall mitochondrial function under these conditions
have been reported, the new proteomics results can inﬂuence
interpretation of the earlier studies.
Two recent reports have applied ATP-acylphosphate probes to
characterizing the ATP-binding proteins of mycobacterium tuber-
culosis (Mtb) [51,52]. Wolfe et al., proﬁled Mtb growing under nor-
mal and hypoxic conditions, whereas Ansong et al., proﬁled only
exponentially growing Mtb, resulting in the identiﬁcation of 122
and 317 proteins, respectively. The difference in the number of
proteins identiﬁed could arise from a number of factors, including
slightly different probes used in the two reports (biotinylated
probe versus click reaction performed after probe labeling) and
different criteria for determining which peptide ID’s are ‘‘real’’ as
Wolfe et al., identiﬁed probe-labeled peptides whereas Ansong
et al., analyzed only non-probe labeled peptides. Taking these
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ATP-binding, numerous of these already having been shown to be
essential for Mtb viability. It is possible that such investigations
will uncover much-needed novel, druggable targets for
tuberculosis.8. Conclusions
The rise of activity-based proteomic proﬁling (ABPP) has served
as a translational testimony to the decades of bio-organic chemis-
try and mechanistic enzymology that developed the underlying
principles of enzymatic catalysis and of the chemistry of protein-
small molecule interactions. The complexities and necessities of ki-
nome drug discovery, human and cross-species, have proven to be
worthy opponents to test the abilities of these venerable biochem-
ical principles to provide new interdisciplinary approaches to the
challenge. In response, an array of protein kinase proﬁling technol-
ogies have emerged incorporating state-of-the-art technological
advances in separations and mass spectrometry with these bio-
chemical principles. The results have given discovery and develop-
ment scientists a variety of proﬁling choices ranging from
relatively simple substrate-based assays of single recombinant ki-
nases to an integrated, simultaneous and quantitative analysis of
virtually every native protein kinase in a proteomic sample.
The acylphosphates of ATP and ADP have demonstrated great
potential in chemoproteomic kinase analysis. Simple in chemical
design and activity-based action, these acylphosphates can provide
a broad, unbiased, sensitive and accurate kinome status in any cell
or tissue from any species. The value to the discovery and develop-
ment of potent and selective kinase inhibitors has been demon-
strated in a variety of in vitro and in vivo settings. Future work
exploring the full spectrum of ATPases interrogated by these acyl-
phosphates promises to expand their utility into new regions of
ATP-binding space. In addition, the potential of the acylphosphates
of other nucleotides, such as GTP, is high and will yield fresh in-
sights into other important areas of nucleotide-binding space.
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